分组1 - ElectroCore, Inc. reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of a loss of $0.56, and an improvement from a loss of $0.53 per share a year ago, resulting in an earnings surprise of 16.07% [1] - The company posted revenues of $6.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.12%, but showing an increase from $5.44 million in the same quarter last year [2] - ElectroCore shares have declined approximately 57% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $7.62 million, and for the current fiscal year, it is -$1.36 on revenues of $31.44 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 26% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Core Viewpoint - Central Garden (CENT) reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.94 per share, and showing an increase from $0.99 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was 10.64%, with a significant prior quarter surprise of 800% when the company reported earnings of $0.21 per share against an expected loss of $0.03 [2] - Revenue for the quarter was $833.54 million, which fell short of the Zacks Consensus Estimate by 4.76% and decreased from $900.09 million year-over-year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has only topped revenue estimates once [3] Stock Performance and Outlook - Central Garden shares have declined approximately 11% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [4] - The company's earnings outlook is mixed, with current consensus EPS estimates of $1.32 for the upcoming quarter and $2.37 for the current fiscal year, alongside expected revenues of $1.01 billion and $3.23 billion respectively [8] Industry Context - The Consumer Products - Discretionary industry, to which Central Garden belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9] - The performance of Central Garden's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]

Core Viewpoint - Groupon reported quarterly earnings of $0.18 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.20 per share, marking an earnings surprise of 190% [1] - The company generated revenues of $117.19 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.46%, although this represents a decline from $123.08 million year-over-year [2] Group 1: Earnings Performance - Groupon's earnings of $0.18 per share compare favorably to earnings of $0.06 per share a year ago, indicating growth [1] - The company has surpassed consensus EPS estimates two times over the last four quarters [2] Group 2: Revenue Insights - The reported revenue of $117.19 million exceeded the consensus estimate, but is lower than the previous year's revenue of $123.08 million [2] - Groupon has topped consensus revenue estimates three times in the last four quarters [2] Group 3: Stock Performance and Outlook - Groupon shares have increased by approximately 39.3% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The company's future stock performance will largely depend on management's commentary during the earnings call [3][4] Group 4: Earnings Estimates and Industry Context - Current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $119.22 million, and -$0.25 on revenues of $497.1 million for the current fiscal year [7] - The Internet - Commerce industry is currently ranked in the top 31% of Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Helmerich & Payne (HP) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -96.92%. A quarter ago, it was expected that this oil and gas well-drilling contractor would post earnings of $0.69 per share when it actually produced earnings of $0.71, delivering a surprise of 2.90%.Over the las ...

Company Performance - F&G Annuities & Life, Inc. reported quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $1.19 per share, and down from $0.86 per share a year ago, representing an earnings surprise of -39.50% [1] - The company posted revenues of $908 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 38.36%, compared to $1.57 billion in revenues a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - F&G Annuities & Life, Inc. shares have lost about 14.1% since the beginning of the year, while the S&P 500 has declined by -4.7% [3] - The current status of estimate revisions is unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $1.20 on revenues of $1.52 billion, and for the current fiscal year, it is $5.05 on revenues of $6.18 billion [7] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [3][4] Industry Context - The Insurance - Life Insurance industry is currently in the bottom 43% of over 250 Zacks industries, suggesting that the outlook for the industry can materially impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Vir Biotechnology reported a quarterly loss of $0.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, and compared to a loss of $0.48 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $3.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 84.51%, and a sharp decline from year-ago revenues of $56.38 million [2] - Over the last four quarters, Vir Biotechnology has only surpassed consensus EPS estimates once, indicating ongoing challenges in meeting market expectations [2] Stock Performance - Since the beginning of the year, Vir Biotechnology shares have lost approximately 23.3%, significantly underperforming the S&P 500, which declined by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.84 on revenues of $15.97 million, and for the current fiscal year, it is -$3.40 on revenues of $61.56 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Vir Biotechnology belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a relatively strong position within the sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Vir Biotechnology's stock performance [5]

Core Insights - BGSF reported a quarterly loss of $0.07 per share, outperforming the Zacks Consensus Estimate of a loss of $0.18, marking an earnings surprise of 61.11% [1] - The company generated revenues of $63.23 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 1.99%, but down from $68.77 million year-over-year [2] - BGSF shares have declined approximately 35.9% year-to-date, contrasting with the S&P 500's decline of 4.7% [3] Earnings Outlook - The future performance of BGSF's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - Current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $69.63 million, and -$0.03 on revenues of $280.25 million for the current fiscal year [7] Industry Context - The Business - Services industry, to which BGSF belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ZipRecruiter, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of -142.9% [9]

Core Insights - Backblaze, Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.06, and improved from a loss of $0.14 per share a year ago, representing a 50% earnings surprise [1] - The company achieved revenues of $34.61 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.08% and showing a year-over-year increase from $29.97 million [2] - Backblaze has consistently exceeded consensus EPS estimates over the last four quarters [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $35.18 million, and for the current fiscal year, it is -$0.15 on revenues of $143.8 million [7] - The estimate revisions trend for Backblaze is currently unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Backblaze belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Backblaze's stock performance [5]

Core Viewpoint - Inogen reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.62 per share a year ago [1][2] Financial Performance - The company achieved revenues of $82.28 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26% and showing an increase from $78.03 million in the same quarter last year [3] - Inogen has surpassed consensus EPS estimates in all four of the last quarters [2][3] Stock Performance - Inogen shares have declined approximately 22.9% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [4] - The current Zacks Rank for Inogen is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $91.8 million, and for the current fiscal year, it is -$1.41 on revenues of $352.81 million [8] - The trend of estimate revisions for Inogen is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%. Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items. There are no easy answers to this key questi ...